224 related articles for article (PubMed ID: 28850029)
21. Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study.
Hung MH; Tien YC; Chiu YM
Adv Rheumatol; 2021 Apr; 61(1):22. PubMed ID: 33832541
[TBL] [Abstract][Full Text] [Related]
22. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
23. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
[TBL] [Abstract][Full Text] [Related]
24. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy.
Ditto MC; Parisi S; Varisco V; Talotta R; Batticciotto A; Antivalle M; Gerardi MC; Agosti M; Borrelli R; Fusaro E; Sarzi-Puttini P
Clin Exp Rheumatol; 2021; 39(3):546-554. PubMed ID: 32940216
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
27. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.
Solay AH; Acar A; Eser F; Kuşcu F; Tütüncü EE; Kul G; Şentürk GÇ; Gürbüz Y
Turk J Gastroenterol; 2018 Sep; 29(5):561-565. PubMed ID: 30260778
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
29. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study.
Giannitti C; Lopalco G; Vitale A; Rigante D; Anelli MG; Fabbroni M; Manganelli S; Galeazzi M; Frediani B; Barone M; Lapadula G; Iannone F; Cantarini L
Clin Exp Rheumatol; 2017; 35(1):93-97. PubMed ID: 27974094
[TBL] [Abstract][Full Text] [Related]
32. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
34. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
[TBL] [Abstract][Full Text] [Related]
35. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
Schwaneck EC; Krone M; Kreissl-Kemmer S; Weißbrich B; Weiss J; Tony HP; Gadeholt O; Schmalzing M; Geier A
Clin Rheumatol; 2018 Nov; 37(11):2963-2970. PubMed ID: 30238380
[TBL] [Abstract][Full Text] [Related]
36. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.
Charpin C; Guis S; Colson P; Borentain P; Mattéi JP; Alcaraz P; Balandraud N; Thomachot B; Roudier J; Gérolami R
Arthritis Res Ther; 2009; 11(6):R179. PubMed ID: 19941642
[TBL] [Abstract][Full Text] [Related]
37. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
[TBL] [Abstract][Full Text] [Related]
38. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
39. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
[TBL] [Abstract][Full Text] [Related]
40. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
